Blueprint Medicines Corp. filings document the company’s biopharmaceutical issuer history, common stock registration, governance votes and corporate-status reporting. Recent Form 8-K disclosures include annual meeting matters such as director elections and advisory executive compensation votes, while Form 15 records the termination of registration or suspension of Exchange Act reporting duties for the company’s common stock.
The filing record also reflects capital-structure disclosure, stockholder voting procedures, registered-security information and material-event reporting associated with Blueprint Medicines’ public-company obligations.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
FAQ
How many Blueprint Medicines Corporation (BPMC) SEC filings are available on StockTitan?
StockTitan tracks 37 SEC filings for Blueprint Medicines Corporation (BPMC), including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and Form 4 insider trading disclosures. Each filing includes AI-generated summaries, impact scoring, and sentiment analysis.
When was the most recent SEC filing for Blueprint Medicines Corporation (BPMC)?
The most recent SEC filing for Blueprint Medicines Corporation (BPMC) was filed on July 21, 2025.